ME02818B - Stab ilna tečna formulacija amg 416 (velkalcetida) - Google Patents
Stab ilna tečna formulacija amg 416 (velkalcetida)Info
- Publication number
- ME02818B ME02818B MEP-2017-150A MEP2017150A ME02818B ME 02818 B ME02818 B ME 02818B ME P2017150 A MEP2017150 A ME P2017150A ME 02818 B ME02818 B ME 02818B
- Authority
- ME
- Montenegro
- Prior art keywords
- formulation
- formulation according
- concentration
- amo
- fact
- Prior art date
Links
- ANIAZGVDEUQPRI-ZJQCGQFWSA-N etelcalcetide Chemical compound NC(N)=NCCC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O ANIAZGVDEUQPRI-ZJQCGQFWSA-N 0.000 title claims 2
- 229950006502 etelcalcetide Drugs 0.000 title claims 2
- 108091022127 etelcalcetide hydrochloride Proteins 0.000 title claims 2
- 239000012669 liquid formulation Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000007864 aqueous solution Substances 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 238000000354 decomposition reaction Methods 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000008181 tonicity modifier Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000008362 succinate buffer Substances 0.000 claims 1
- 150000003890 succinate salts Chemical group 0.000 claims 1
Classifications
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
- F04D—NON-POSITIVE-DISPLACEMENT PUMPS
- F04D25/00—Pumping installations or systems
- F04D25/02—Units comprising pumps and their driving means
- F04D25/06—Units comprising pumps and their driving means the pump being electrically driven
- F04D25/0606—Units comprising pumps and their driving means the pump being electrically driven the electric motor being specially adapted for integration in the pump
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
- F01D—NON-POSITIVE DISPLACEMENT MACHINES OR ENGINES, e.g. STEAM TURBINES
- F01D15/00—Adaptations of machines or engines for special use; Combinations of engines with devices driven thereby
- F01D15/10—Adaptations for driving, or combinations with, electric generators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (15)
1. Farmaceutska formulacija koja sadrži AMO 4 16 u vodenom rastvoru, naznačena time što formulacija ima pH od 2.0 do 5.0.
2. Formulacija prema patentnom zahtevu l, naznače na time što formulacija ima pH od 2.5 do 4.5.
3.Formulacija prema patentnom zahtevu l, nazn ačena time što formulacija ima pH od 2.5 do 4.0.
4.Formulacija prema patentnom zahtevu l , naznačena time što formulacija ima pH od 3.0 do 3.5.
5.Formulacija prema patentnom zahtevu l , naznačena time što je pH održavana pomoću farmaceutski prihvat lj ivog pufera.
6.Formulacija prema patentnom zahtevu 5, naznačena time štopufer je sukcinat.
7.Formulacija prema patentnom zahtevu l, naznačena time što AMO 416 je prisutan u formulaciji u koncentraciji od 0.1 mg/mL do 20 mg/mL
8.Formulacija prema patentnom zahtevu l, naznačena time što je AMO 416 prisutan u formulaciji u koncentraciji od l mg/mL do 15 mg/mL.
9.Formulacija prema patentnom zahtevu l, naznačena time što je AMO 416 prisutan u formulaciji u koncentraciji od 2.5 mg/mL do l O mg/mL.
10.Formulacija prema patentnom zahtevu l, koja dalje sadrži farmace utski prihvatljiv modifikator toničnosti.
11.ll. Formulacija prema patentnom zahtevu l O, naznačena time što je modifikator toničnosti prisutan u formulaciji u koncentraciji koja je dovoljna da formulacija bude približno izotonična.
12.Formulacija prema patentnom zahtevu l O, naznačena time što regulator toni čnosti je NaCl.
13.Formulacija prema patentnom zahtevu l, naznačena time što formulacija ima manje od l 0% razlaganja kada je čuvana na 2-8°C tokom 2 godine.
14.Formulacija prema patentnom zahtevu l, naznačena time što formulacija ima manje od l 0% razlaganja kada je čuvana na sobnoj temperaturi tokom 2 godine.
15.Formulacija koja sadrži 2 mg/mL do 20 mg/mL AMG 416 u vodenom rastvoru, sukcinatni pufer koji održava formu laciju na pH od oko 3.0 do 3.5, i dovoljnu koncentraciju natrijum hlorida da bi formu lacija bila približno izotonična.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361840618P | 2013-06-28 | 2013-06-28 | |
| PCT/US2014/044622 WO2014210489A1 (en) | 2013-06-28 | 2014-06-27 | Stable liquid formulation of amg 416 (velcalcetide) |
| EP14742093.9A EP3013318B1 (en) | 2013-06-28 | 2014-06-27 | Stable liquid formulation of amg 416 (velcalcetide) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02818B true ME02818B (me) | 2018-01-20 |
Family
ID=51213030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-150A ME02818B (me) | 2013-06-28 | 2014-06-27 | Stab ilna tečna formulacija amg 416 (velkalcetida) |
Country Status (38)
| Country | Link |
|---|---|
| US (4) | US9820938B2 (me) |
| EP (3) | EP3246017B1 (me) |
| JP (1) | JP6027708B2 (me) |
| KR (1) | KR102231957B1 (me) |
| CN (2) | CN114376970A (me) |
| AP (1) | AP2015008936A0 (me) |
| AR (1) | AR096773A1 (me) |
| AU (1) | AU2014302122B2 (me) |
| CA (1) | CA2916222C (me) |
| CL (1) | CL2015003738A1 (me) |
| CR (2) | CR20160061A (me) |
| CY (1) | CY1120811T1 (me) |
| DK (1) | DK3013318T3 (me) |
| EA (1) | EA030220B1 (me) |
| ES (1) | ES2633989T3 (me) |
| HR (1) | HRP20171092T1 (me) |
| HU (1) | HUE034209T2 (me) |
| IL (1) | IL243210B (me) |
| JO (1) | JO3817B1 (me) |
| LT (1) | LT3013318T (me) |
| MA (1) | MA38724B1 (me) |
| ME (1) | ME02818B (me) |
| MX (1) | MX2015017952A (me) |
| MY (1) | MY180276A (me) |
| PE (2) | PE20160549A1 (me) |
| PH (1) | PH12015502816A1 (me) |
| PL (1) | PL3013318T3 (me) |
| PT (1) | PT3013318T (me) |
| RS (1) | RS56238B1 (me) |
| SG (1) | SG11201510647TA (me) |
| SI (1) | SI3013318T1 (me) |
| SM (1) | SMT201700401T1 (me) |
| TN (1) | TN2015000569A1 (me) |
| TW (1) | TWI635874B (me) |
| UA (1) | UA115373C2 (me) |
| UY (1) | UY35636A (me) |
| WO (1) | WO2014210489A1 (me) |
| ZA (1) | ZA201600238B (me) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114376970A (zh) | 2013-06-28 | 2022-04-22 | 美国安进公司 | Etelcalcetide (AMG 416)的稳定的液体制剂 |
| US10407464B2 (en) | 2014-04-03 | 2019-09-10 | Amgen Inc. | Method for preparing AMG 416 |
| US10858389B2 (en) | 2015-03-26 | 2020-12-08 | Amgen Inc. | Solution phase method for preparing etelcalcetide |
| CN106137979A (zh) * | 2015-03-31 | 2016-11-23 | 深圳翰宇药业股份有限公司 | 一种冻干粉针剂及其制备方法 |
| CN106928320B (zh) | 2015-12-31 | 2021-01-15 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| CN106928321B (zh) * | 2015-12-31 | 2019-07-26 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| CN110054662B (zh) * | 2018-01-18 | 2021-03-02 | 成都圣诺生物制药有限公司 | 一种固相合成Etelcalcetide的方法 |
| EP4149507A1 (en) | 2020-05-15 | 2023-03-22 | Amgen Inc. | Methods of treating left ventricle hypertrophy |
| CN111925415A (zh) * | 2020-08-10 | 2020-11-13 | 海南中和药业股份有限公司 | 一种维拉卡肽杂质的制备方法 |
| WO2022034545A1 (en) * | 2020-08-14 | 2022-02-17 | Aurobindo Pharma Limited | Etelcalcetide formulations for parenteral use |
| US20240207354A1 (en) | 2021-05-06 | 2024-06-27 | Amgen Inc. | Etelcalcetide formulations |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69703121D1 (de) | 1996-10-25 | 2000-10-19 | Us Health | Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit |
| AT409081B (de) | 2000-02-16 | 2002-05-27 | Gebro Pharma Gmbh | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung |
| JP4936884B2 (ja) * | 2003-06-03 | 2012-05-23 | ノボ・ノルデイスク・エー／エス | 安定化された薬学的ペプチド組成物 |
| WO2004105781A2 (en) | 2003-06-03 | 2004-12-09 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
| US7265092B2 (en) | 2004-09-30 | 2007-09-04 | Kai Pharmaceuticals, Inc. | Pharmaceutical formulation |
| US8987200B2 (en) * | 2006-11-16 | 2015-03-24 | Kai Pharmaceuticals, Inc. | Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders |
| AU2008206077A1 (en) | 2007-01-19 | 2008-07-24 | Kai Pharmaceuticals, Inc. | Modifications of peptide compositions to increase stability and delivery efficiency |
| EP2264138B2 (en) | 2009-06-19 | 2023-03-08 | The Procter & Gamble Company | Liquid hand dishwashing detergent composition |
| EP4154900B1 (en) | 2009-07-29 | 2024-08-28 | Kai Pharmaceuticals, Inc. | Therapeutic agents for reducing parathyroid hormone levels |
| EP2399604A1 (en) | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| WO2012075375A1 (en) * | 2010-12-02 | 2012-06-07 | Lanco Biosciences, Inc. | Delivery of parathyroid hormones by microinjection systems |
| LT2717896T (lt) * | 2011-06-08 | 2017-02-27 | Kai Pharmaceuticals, Inc. | Terapiniai agentai, skirti fosforo koncentracijos serume reguliavimui |
| US20140315809A1 (en) | 2011-11-10 | 2014-10-23 | Kai Pharmaceuticals, Inc. | Calcimimetics and methods for their use |
| CN114376970A (zh) | 2013-06-28 | 2022-04-22 | 美国安进公司 | Etelcalcetide (AMG 416)的稳定的液体制剂 |
| US10407464B2 (en) * | 2014-04-03 | 2019-09-10 | Amgen Inc. | Method for preparing AMG 416 |
-
2014
- 2014-06-27 CN CN202111597304.7A patent/CN114376970A/zh active Pending
- 2014-06-27 SG SG11201510647TA patent/SG11201510647TA/en unknown
- 2014-06-27 EA EA201690099A patent/EA030220B1/ru not_active IP Right Cessation
- 2014-06-27 EP EP17160312.9A patent/EP3246017B1/en active Active
- 2014-06-27 PT PT147420939T patent/PT3013318T/pt unknown
- 2014-06-27 ME MEP-2017-150A patent/ME02818B/me unknown
- 2014-06-27 US US14/908,481 patent/US9820938B2/en active Active
- 2014-06-27 ES ES14742093.9T patent/ES2633989T3/es active Active
- 2014-06-27 LT LTEP14742093.9T patent/LT3013318T/lt unknown
- 2014-06-27 AP AP2015008936A patent/AP2015008936A0/xx unknown
- 2014-06-27 HR HRP20171092TT patent/HRP20171092T1/hr unknown
- 2014-06-27 PE PE2015002666A patent/PE20160549A1/es unknown
- 2014-06-27 CR CR20160061A patent/CR20160061A/es unknown
- 2014-06-27 KR KR1020167002370A patent/KR102231957B1/ko active Active
- 2014-06-27 PE PE2020001772A patent/PE20210413A1/es unknown
- 2014-06-27 EP EP14742093.9A patent/EP3013318B1/en active Active
- 2014-06-27 HU HUE14742093A patent/HUE034209T2/en unknown
- 2014-06-27 EP EP21156687.2A patent/EP3878433A1/en active Pending
- 2014-06-27 SI SI201430290T patent/SI3013318T1/sl unknown
- 2014-06-27 SM SM20170401T patent/SMT201700401T1/it unknown
- 2014-06-27 JP JP2016524250A patent/JP6027708B2/ja active Active
- 2014-06-27 MX MX2015017952A patent/MX2015017952A/es active IP Right Grant
- 2014-06-27 MA MA38724A patent/MA38724B1/fr unknown
- 2014-06-27 CR CR20160002A patent/CR20160002A/es unknown
- 2014-06-27 PL PL14742093T patent/PL3013318T3/pl unknown
- 2014-06-27 WO PCT/US2014/044622 patent/WO2014210489A1/en not_active Ceased
- 2014-06-27 TN TN2015000569A patent/TN2015000569A1/en unknown
- 2014-06-27 AU AU2014302122A patent/AU2014302122B2/en active Active
- 2014-06-27 RS RS20170704A patent/RS56238B1/sr unknown
- 2014-06-27 MY MYPI2015003044A patent/MY180276A/en unknown
- 2014-06-27 CA CA2916222A patent/CA2916222C/en active Active
- 2014-06-27 CN CN201480047399.7A patent/CN105764487A/zh active Pending
- 2014-06-27 UA UAA201600641A patent/UA115373C2/uk unknown
- 2014-06-27 DK DK14742093.9T patent/DK3013318T3/en active
- 2014-06-27 TW TW103122433A patent/TWI635874B/zh active
- 2014-06-29 JO JOP/2014/0204A patent/JO3817B1/ar active
- 2014-06-30 UY UY0001035636A patent/UY35636A/es not_active Application Discontinuation
- 2014-06-30 AR ARP140102450A patent/AR096773A1/es not_active Application Discontinuation
-
2015
- 2015-12-17 IL IL243210A patent/IL243210B/en active IP Right Grant
- 2015-12-17 PH PH12015502816A patent/PH12015502816A1/en unknown
- 2015-12-28 CL CL2015003738A patent/CL2015003738A1/es unknown
-
2016
- 2016-01-12 ZA ZA2016/00238A patent/ZA201600238B/en unknown
-
2017
- 2017-07-19 CY CY171100771T patent/CY1120811T1/el unknown
- 2017-11-02 US US15/802,390 patent/US10344765B2/en active Active
-
2019
- 2019-06-03 US US16/430,322 patent/US11162500B2/en active Active
-
2021
- 2021-08-11 US US17/400,044 patent/US11959486B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171092T1 (hr) | Stabilna tekuća formulacija amg 416 (velkalcetid) | |
| AR134413A2 (es) | Composiciones de insulina de rápida acción | |
| HRP20191477T1 (hr) | Farmaceutski sastav s-ketamin hidroklorida | |
| CL2013000815A1 (es) | Composicion farmaceutica liquida de adm inistracion parenteral que comprende dexmedetomidina o una sal de la misma en una concentracion de 0,005 a 50 µg/ml y adicionalmente comprende cloruro de sodio en una concentracion de 0,01 a 2 % en peso, dispuesta dentro de un contenedor de vidrio sellado. | |
| EA201591003A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| ECSP16084431A (es) | Composiciones estables de yodo no en complejo y métodos de uso | |
| JP2015527402A5 (me) | ||
| MX362985B (es) | Concentrados herbicidas acuosos. | |
| AR086651A1 (es) | Dentifrico de ion metalico con bajo contenido de agua | |
| RU2013124024A (ru) | Фармацевтическая композиция, содержащая мометазона фуроат и азеластина гидрохлорид, назального введения | |
| CO2017007137A2 (es) | Composición farmacéutica que comprende plasminógeno y usos de este | |
| BR112016025126A8 (pt) | Formulação líquida compreendendo composto neutralizante de gm-csf | |
| PY1407911A (es) | Composición de glifosato para mezclas de tanque con dicamba con volatilidad mejorada | |
| MX374628B (es) | Formulacion que comprende un agente hipolipidemico. | |
| EA201600118A1 (ru) | Жидкая водная фармацевтическая композиция с консервантами, содержащая этерифицированные производные циклодекстрина | |
| RU2016147362A (ru) | Препараты жидкого концетрата циклофосфамида | |
| CY1122387T1 (el) | Διπλης χρησης δισκια στοματικης φαρμακευτικης συνθεσης θειικων αλατων και μεθοδοι χρησης αυτων | |
| HRP20220793T1 (hr) | Oftalmološki vodeni sastav | |
| BR112019005542A2 (pt) | composições para compostos de agente terapêutico de pequenas moléculas | |
| AR096704A1 (es) | Formulación detergente higroscópica que comprende agua, agente quelante aminocarboxilato e ingredientes sensibles a la humedad | |
| AR087371A1 (es) | Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos | |
| CL2017001039A1 (es) | Composiciones anti-transpirantes anhidras | |
| ECSP11010856A (es) | Composición farmacéutica sólida | |
| BR112015025058A8 (pt) | Composição farmacêutica do tipo matriz contendo lacosamida | |
| HRP20201161T1 (hr) | Formulacije sa smanjenom oksidacijom |